Can I Take Quercetin with Repatha (Evolocumab)? A Women's Health Guide

What Is Repatha and Why Do Women Take It?

Repatha (evolocumab) is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. By neutralizing PCSK9, evolocumab keeps more LDL receptors active on the liver surface, which pulls more LDL cholesterol out of circulation. The FOURIER trial showed that adding evolocumab to statin therapy reduced LDL-C by a median of 59% and cut the risk of major adverse cardiovascular events by 15% over a median 2.2 years of follow-up in over 27,500 patients.

Women use evolocumab for two main indications approved by the FDA: heterozygous or homozygous familial hypercholesterolemia (FH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL lowering beyond what statins and ezetimibe can achieve.

Women-Specific Cardiovascular Context

Cardiovascular disease is the leading cause of death in women in the United States, accounting for one in every five female deaths. Yet women have historically been under-represented in lipid-lowering trials. In FOURIER, only about 25% of participants were female, meaning the trial was not powered to detect sex-specific outcome differences. What we know about evolocumab's efficacy in women is largely extrapolated from the pooled analysis rather than a female-primary dataset. This is an evidence gap you deserve to know about.

Life-Stage Differences in Who Gets Prescribed Evolocumab

• Reproductive years. Women with heterozygous FH may need aggressive LDL lowering even before age 40. PCOS is also associated with dyslipidemia, and some women with PCOS and very high LDL may eventually reach the threshold for a PCSK9 inhibitor, though statin therapy typically comes first.
• Perimenopause. The estrogen withdrawal of perimenopause drives LDL-C upward by 10 to 15 mg/dL on average in many women. This can push someone who was previously well-controlled into a range that requires escalation of lipid therapy.
• Post-menopause. This is the life stage where most women with established ASCVD who need evolocumab will be found. LDL receptor expression may also be influenced by lower estrogen levels, though the clinical significance of this for PCSK9 inhibitor response has not been well-studied in dedicated female cohorts.

What Is Quercetin and Why Women Take It

Quercetin is a flavonoid polyphenol found in onions, apples, capers, and green tea. As a supplement, typical doses range from 250 mg to 1,000 mg per day, sometimes formulated with bromelain or vitamin C to improve absorption.

Women reach for quercetin for a range of reasons: anti-inflammatory support, allergy relief (its mast-cell stabilizing properties mimic antihistamines), and cardiovascular benefits including modest LDL reduction and blood pressure effects. A 2016 meta-analysis in the British Journal of Nutrition found that quercetin supplementation at doses of 500 mg/day or more reduced systolic blood pressure by a mean of 3.04 mmHg compared to placebo.

Female-Relevant Reasons Women Use Quercetin

• Hormonal acne and PCOS. Quercetin has weak anti-androgenic properties in cell models, and some women with PCOS take it hoping to reduce androgen-driven symptoms. Human trial evidence for this is limited.
• Perimenopause symptoms. Quercetin's phytoestrogen-like signaling at low potency has been explored for symptom management, though it should not be conflated with estrogen therapy.
• Endometriosis. Quercetin inhibits certain inflammatory mediators including COX-2, and some practitioners suggest it for symptom support in endometriosis, though randomized trial data in women is sparse.
• Bone health. Preclinical data suggest quercetin may reduce osteoclast activity, relevant to the accelerated bone loss of perimenopause and post-menopause. Human evidence remains preliminary.

The Interaction Mechanism: Pharmacokinetics vs. Pharmacodynamics

This is the section that matters most for your safety, so the distinction between these two types of interactions deserves careful attention.

Pharmacokinetic Interaction: Why It Is Lower Than With Statins

Evolocumab is a monoclonal antibody. Unlike small-molecule drugs such as statins (which are metabolized heavily by CYP3A4 and CYP2C9), evolocumab is broken down by the same proteolytic pathways that degrade all endogenous antibodies and proteins. It does not rely on CYP450 enzymes for metabolism, and it does not require P-glycoprotein transport into cells.

Quercetin is a known inhibitor of CYP3A4, CYP2C9, and P-glycoprotein in vitro, and these effects have been demonstrated in some human pharmacokinetic studies with co-administered drugs that depend on those pathways. Because evolocumab does not travel those metabolic routes, quercetin's CYP3A4 inhibition is unlikely to raise evolocumab blood levels or prolong its half-life in a clinically meaningful way.

This is a meaningful distinction. If you were asking about quercetin with atorvastatin (a CYP3A4 substrate), the pharmacokinetic concern would be more direct. With evolocumab, it is much less of a primary worry.

Pharmacodynamic Interaction: The Real Consideration

A pharmacodynamic interaction occurs when two agents affect the same physiological endpoint, independent of how either drug is metabolized. Here, both quercetin and evolocumab influence cardiovascular and lipid-related pathways.

• Additive LDL lowering. Quercetin may modestly reduce LDL cholesterol. A 2021 meta-analysis in Phytotherapy Research found a small but statistically significant reduction in LDL-C with quercetin supplementation. Combining this with evolocumab's potent LDL reduction is unlikely to cause harm from overly low LDL, but it can complicate interpretation of lab results and dose decisions.
• Blood pressure effects. Both agents may lower blood pressure. If you are already on antihypertensive medications, the combination could contribute to hypotension, especially at higher quercetin doses.
• Anti-inflammatory overlap. Evolocumab has been associated with reductions in hsCRP in some analyses. Quercetin also reduces certain inflammatory markers. Overlapping anti-inflammatory activity is unlikely to be dangerous, but the additive effect has not been studied in a controlled setting.
• Platelet and anticoagulation effects. Quercetin has mild antiplatelet properties. If you are on anticoagulants or antiplatelet therapy alongside evolocumab, this becomes a separate consideration that warrants clinician review.

The framework that best describes this interaction: low pharmacokinetic risk, uncertain but plausible pharmacodynamic overlap, and a genuine evidence gap because no published human trial has directly tested quercetin plus evolocumab together. The absence of a documented interaction in databases does not mean the combination has been studied and cleared. It means it has not been studied.

What Current Evidence and Databases Say

No randomized controlled trial has examined quercetin co-administered with evolocumab in human participants. This is an honest statement of the evidence base. What we have instead:

• Natural Medicines database classifies the quercetin-plus-lipid-lowering-drug category as warranting monitoring due to additive lipid effects, rather than a hard contraindication.
• In vitro and animal data show quercetin's CYP enzyme inhibition, which is relevant for co-prescribed statins but not for the biologic pathway that evolocumab follows.
• The ODYSSEY OUTCOMES trial and FOURIER both excluded patients on supplements at high doses, meaning the trials that established evolocumab's safety profile were conducted without accounting for supplement co-use. This exclusion is a gap in real-world applicability.
• A 2020 review in Nutrients specifically examined quercetin's cardiovascular effects and concluded that while cardiovascular benefits are plausible, drug interaction studies are systematically lacking.

Women are more likely than men to use dietary supplements alongside prescription medications. A CDC National Health and Nutrition Examination Survey analysis found that approximately 80% of women over 60 use at least one dietary supplement. Given that post-menopausal women make up a large share of the ASCVD population on PCSK9 inhibitors, this interaction gap has real-world consequences for you.

Pregnancy and Lactation: What You Must Know

Evolocumab in pregnancy: not recommended. The FDA has not assigned a formal pregnancy category to evolocumab under the current labeling system (which replaced letter categories in 2015), but the evolocumab prescribing information states that animal reproductive studies showed no adverse developmental outcomes at doses up to 12 times the human exposure, but that human pregnancy data are insufficient to determine risk. The general principle that LDL cholesterol is necessary for fetal steroid hormone synthesis means aggressive LDL lowering during pregnancy raises theoretical concern. Evolocumab should be discontinued when pregnancy is recognized unless the clinical benefit clearly outweighs unknown risk, and this decision requires specialist involvement.

Quercetin in pregnancy: insufficient data. No adequate human studies exist on quercetin supplementation during pregnancy. At high doses, quercetin has shown embryotoxic effects in animal models. The prudent recommendation is to discontinue quercetin supplements before attempting conception and throughout pregnancy.

Lactation. Human data are absent for both agents in breastfeeding. Evolocumab is a large-molecule biologic unlikely to transfer substantially into breast milk or survive infant gut digestion in meaningful amounts, but this has not been formally studied. Quercetin does transfer into breast milk in animal models, but the clinical significance for a human infant is unknown. The conservative guidance is to avoid both unless specifically directed by your clinician.

Contraception requirement. Women of reproductive potential who require evolocumab for familial hypercholesterolemia should use reliable contraception during treatment given the absence of human pregnancy safety data. Discuss contraception with your prescriber. If you are taking a combined hormonal contraceptive, be aware that some oral contraceptives increase LDL-C, which adds complexity to lipid monitoring.

Who This Is Right For, and Who Should Be More Careful

Women Who May Be Able to Take Both (With Monitoring)

• Post-menopausal women on evolocumab for established ASCVD who use low-to-moderate dose quercetin (250 to 500 mg/day) for anti-inflammatory support, provided their LDL-C, blood pressure, and liver enzymes are monitored regularly.
• Women who have discussed the combination explicitly with their cardiologist or lipid specialist and have a clear reason for adding quercetin.
• Women whose LDL-C target is comfortably met and who are not on anticoagulants or additional antihypertensives that could amplify additive effects.

Women Who Should Be More Cautious

• Women of reproductive age on evolocumab who may become pregnant. Quercetin supplements should be stopped well before any planned conception.
• Women on anticoagulants (warfarin, apixaban, rivaroxaban) or multiple antihypertensives alongside evolocumab. Quercetin's antiplatelet and blood-pressure effects add complexity.
• Women with heterozygous or homozygous FH whose LDL-C control is precarious and who need clean, interpretable lab trends to guide dosing decisions.
• Women with PCOS who are taking quercetin for androgenic symptoms and whose prescribers have not been told about the supplement use. Transparency with your full supplement list is non-negotiable.

Practical Steps If You Are Already Taking Both

1. Tell your prescriber today. Not at your next annual visit. If you are currently combining quercetin with evolocumab and no one has reviewed this, that conversation should happen at your next available appointment or via your telehealth portal.

2. Check your LDL-C trend. If your LDL-C has dropped significantly since adding quercetin, this may reflect additive activity. Your prescriber may want to review whether your evolocumab dose or injection schedule still needs to remain the same.

3. Review your full medication list for CYP3A4-metabolized drugs. Evolocumab itself does not depend on CYP3A4, but other drugs you may take alongside it (certain statins, calcium channel blockers, some immunosuppressants) do. Quercetin's CYP3A4 inhibition matters more for those co-medications.

4. Note your quercetin dose. Doses at or above 500 mg/day are where pharmacokinetic effects in humans become more plausible based on available data. Doses below 250 mg/day from food sources (onions, apples, tea) carry negligible interaction risk.

5. Monitor blood pressure at home. If you are combining agents with potential additive antihypertensive effects and you notice dizziness, lightheadedness, or readings consistently below your established target, report this.

Monitoring Parameters When Combining Quercetin and Evolocumab

| Parameter | Frequency | What to Watch For | |---|---|---| | LDL-C, total lipid panel | Every 3 to 6 months | Unexpectedly steep LDL drop may indicate additive effect | | Blood pressure | Monthly at home | Readings below your established target | | Liver enzymes (AST, ALT) | At baseline, then annually | Quercetin at high doses has hepatotoxic potential in animal models | | Injection-site reactions | At each injection | Not quercetin-related; evolocumab standard monitoring | | Symptoms of bleeding or bruising | Ongoing | Relevant if on anticoagulants; quercetin antiplatelet effect |

Sex-Specific Pharmacology Notes

Evolocumab has not been studied with sex-stratified pharmacokinetic data in its key trials to the degree that would allow precise dose adjustment by sex. Women generally have lower body weight and different adipose distribution, and large-molecule biologics can have modestly different volume of distribution in women. The FOURIER sex-stratified sub-analysis did not find a statistically significant difference in relative risk reduction between men and women, but confidence intervals were wide in the female subgroup, consistent with the under-powered female sample.

Quercetin's metabolism shows some sex-dependent variation. Estrogen influences the activity of COMT (catechol-O-methyltransferase), an enzyme involved in quercetin methylation. This means quercetin's bioavailability and half-life may differ between pre-menopausal and post-menopausal women, though this has not been the primary focus of clinical trials in women.

This is an example of where women's physiology introduces complexity that the existing literature does not yet resolve. Honest acknowledgment of this gap is more useful than false reassurance.

A Note on PCOS, Endometriosis, and Quercetin Use in Women Taking Lipid Therapy

Women with PCOS have a higher baseline risk of dyslipidemia. A 2019 review in the Journal of Clinical Endocrinology and Metabolism reported that women with PCOS had significantly higher LDL-C and triglycerides compared to age-matched controls. Some women with PCOS who are prescribed statins early may progress to needing a PCSK9 inhibitor if FH co-exists.

Quercetin is sometimes suggested in PCOS communities for androgen reduction and ovarian function support, based on small trials. If you are a woman with PCOS on evolocumab who is also using quercetin, your prescriber needs to know. The combination is not automatically unsafe, but it sits in an evidence-free zone that requires personalized clinical judgment.

Women with endometriosis who use quercetin for anti-inflammatory support are unlikely to be on evolocumab unless a separate cardiovascular indication exists. If that situation applies, the same cautions above apply.